Detalles de la búsqueda
1.
Phase 2 study of RO4929097, a gamma-secretase inhibitor, in metastatic melanoma: SWOG 0933.
Cancer
; 121(3): 432-440, 2015 Feb 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-25250858
2.
Combination of vemurafenib and cobimetinib in patients with advanced BRAF(V600)-mutated melanoma: a phase 1b study.
Lancet Oncol
; 15(9): 954-65, 2014 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-25037139
3.
New options for the adjuvant treatment of cutaneous melanoma?
Curr Oncol Rep
; 16(11): 409, 2014 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-25286906
4.
A phase II study of 17-allylamino-17-demethoxygeldanamycin in metastatic or locally advanced, unresectable breast cancer.
Breast Cancer Res Treat
; 131(3): 933-7, 2012 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-22083229
5.
A phase 2 trial of complete resection for stage IV melanoma: results of Southwest Oncology Group Clinical Trial S9430.
Cancer
; 117(20): 4740-06, 2011 Oct 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-21455999
6.
SWOG S0215: a phase II study of docetaxel and vinorelbine plus filgrastim with weekly trastuzumab for HER2-positive, stage IV breast cancer.
Breast Cancer Res Treat
; 130(1): 123-31, 2011 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-21826527
7.
An Open-Label, Randomized, Multi-Center Study Comparing the Sequence of High Dose Aldesleukin (Interleukin-2) and Ipilimumab (Yervoy) in Patients with Metastatic Melanoma.
Oncoimmunology
; 10(1): 1984059, 2021.
Artículo
en Inglés
| MEDLINE | ID: mdl-34650833
8.
Phase II clinical trial using anti-CD3 × anti-HER2 bispecific antibody armed activated T cells (HER2 BATs) consolidation therapy for HER2 negative (0-2+) metastatic breast cancer.
J Immunother Cancer
; 9(6)2021 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-34117114
9.
Immune adverse events (irAEs) with adjuvant ipilimumab in melanoma, use of immunosuppressants and association with outcome: ECOG-ACRIN E1609 study analysis.
J Immunother Cancer
; 9(5)2021 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-33963015
10.
Molecular profiling of melanoma brain metastases compared to primary cutaneous melanoma and to extracranial metastases.
Oncotarget
; 11(33): 3118-3128, 2020 Aug 18.
Artículo
en Inglés
| MEDLINE | ID: mdl-32913556
11.
Phase III Study of Adjuvant Ipilimumab (3 or 10 mg/kg) Versus High-Dose Interferon Alfa-2b for Resected High-Risk Melanoma: North American Intergroup E1609.
J Clin Oncol
; 38(6): 567-575, 2020 02 20.
Artículo
en Inglés
| MEDLINE | ID: mdl-31880964
12.
Cancer Site and Adverse Events Induced by Immune Checkpoint Inhibitors: A Retrospective Analysis of Real-life Experience at a Single Institution.
Anticancer Res
; 39(2): 781-790, 2019 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-30711957
13.
A multi-center phase II study of high dose interleukin-2 sequenced with vemurafenib in patients with BRAF-V600 mutation positive metastatic melanoma.
J Immunother Cancer
; 6(1): 76, 2018 07 27.
Artículo
en Inglés
| MEDLINE | ID: mdl-30053905
14.
High frequency of brain metastases after adjuvant therapy for high-risk melanoma.
Cancer Med
; 6(11): 2576-2585, 2017 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-28994212
15.
Phase III Randomized Study of 4 Weeks of High-Dose Interferon-α-2b in Stage T2bNO, T3a-bNO, T4a-bNO, and T1-4N1a-2a (microscopic) Melanoma: A Trial of the Eastern Cooperative Oncology Group-American College of Radiology Imaging Network Cancer Research Group (E1697).
J Clin Oncol
; 35(8): 885-892, 2017 Mar 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-28135150
16.
Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma.
J Clin Oncol
; 23(1): 133-41, 2005 Jan 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-15625368
17.
Factors associated with breast cancer clinical trials participation and enrollment at a large academic medical center.
J Clin Oncol
; 22(11): 2046-52, 2004 Jun 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-15082724
18.
Adjuvant immunotherapy of resected, intermediate-thickness, node-negative melanoma with an allogeneic tumor vaccine: impact of HLA class I antigen expression on outcome.
J Clin Oncol
; 20(8): 2067-75, 2002 Apr 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-11956267
19.
Adjuvant immunotherapy of resected, intermediate-thickness, node-negative melanoma with an allogeneic tumor vaccine: overall results of a randomized trial of the Southwest Oncology Group.
J Clin Oncol
; 20(8): 2058-66, 2002 Apr 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-11956266
20.
SWOG S0221: a phase III trial comparing chemotherapy schedules in high-risk early-stage breast cancer.
J Clin Oncol
; 33(1): 58-64, 2015 Jan 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-25422488